Search

everythinglearnresearchcommunity

for

Search:↓

Research 10 of 1000+

1. 42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events Journal of the American Academy of Dermatology · 2023
2. Hidradenitis suppurativa and major adverse cardiac events: A systematic review and meta-analysis Journal of The American Academy of Dermatology · 2020 · 7 citations
3. Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications Advances in Therapy · 2023 · 6 citations
4. PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS? 2022
5. Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program American Journal of Clinical Dermatology · 2025 · 1 citations
6. Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program SKIN The Journal of Cutaneous Medicine · 2025
7. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program American journal of clinical dermatology · 2024
8. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials 2022 · 25 citations
9. ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW International Journal of Innovative Technologies in Social Science · 2025
10. JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study Dermatology and Therapy · 2026 · 1 citations

Community

— no results